Mission:
To promote excellence in clinical care through research and education.
 
 
  Learn More...



Current Staff
 
Director:  John W. Goethe, M.D.
Charles Caley, Pharm.D. (UConn)
Bonnie Szarek, R.N.
Alex Cardoni, M.S. Pharm.
Charles Wilber, M.Ed.
Luisa Chmielecki, CCRP
Andrew Winokur, M.D., Ph.D.
Adam Jaffe, Ph.D.
Jeff Wisniowski, M.P.H.
Katherine Karbowski, B.A.
Stephen Woolley, D.Sc., M.P.H.
Sherri Post, B.A.
Brenda Woznicki, B.A.     

 

(top)
 

 
Clinical Information Management
The Burlingame Center supports quality management and program evaluation activities, monitors clinical care (e.g., evidence-based practices), maintains practice guideline documents, and conducts research related to hospital operations.

 

The Clinical Evaluation and Monitoring System (CEMS)
The Burlingame Center operates the hospital's computerized clinical decision support system CEMS.  This automated decision support system, developed by John W. Goethe, M.D. and Bonnie L. Szarek, R.N., supports the goal of assuring the optimal outcome for every patient. The components of the system are:

  • Psychotropic Guidelines: This on-line document summarizes key information about the use of selected psychiatric medications (dosages, therapeutic serum levels, indications and side effects). It also presents "decision trees" to guide drug selection. (more)
  • Information Alerts: These computer-generated messages notify clinicians of events that do not conform to practice guidelines and medication protocols. Clinicians may respond to these notices by changing the treatment plan/diagnosis/laboratory orders to comply with "usual practice" (defined in the Pharmacotherapy Guidelines) or by documenting the reason for alternative treatment, using a standard form to record the response. (The response is then automatically entered as a progress note in the patient’s medical record.)
  • Diagnostic Checklists (DCLs): The DCLs provide an automated method for assuring documentation of the key symptoms and behavioral issues that support the assigned diagnosis and for noting the degree of change in each symptom/behavior at subsequent evaluations (e.g., at discharge). There is a separate checklist for each psychiatric diagnosis that reflects DSM criteria for that diagnosis.
  • Outcome Assessment Program (OAP): Clinical staff interview every patient at admission and discharge, using a brief questionnaire to assess items related to functioning and productivity. The patient is contacted at one, six, and twelve months post-discharge to assess functional status and subsequent psychiatric treatment received.  Manager: Steve Woolley, M.P.H., D.Sc. Coordinator: Brenda Woznicki.
Investigational Therapies Service
This service, directed by Drs. John Goethe and Andrew Winokur, offers access to psychiatric medications that are currently in development but not yet approved for use in routine clinical care. These medications can only be administered to individuals who participate in a formal research study. Click here for information about current studies.

Mood Disorders Consultation Service
The Mood Disorders Consultation Service at The Institute of Living is designed to help people whose mood disorders have so far been resistant to therapy. The behavioral health community increasingly recognizes that recovery—not just response—must be the ultimate goal of therapy. Full recovery is the overarching goal of our program. We continue to work with each patient until we have identified the optimal treatment and outcome. (more)

(top

 

 
Professional Education Activities Include:

Grand Rounds:
Weekly educational conferences covering a variety of topics related to mental health and psychiatric practice.  Grand Rounds are accredited for continuing medical education and are presented Thursday afternoons 12:00 PM - 1:15 PM, September through June. (more)
 
Psychopharmacology and Neuroscience Rounds:
This series focuses on applied psychopharmacology and research on brain structure and function.  Held once monthly from September through June on Wednesday at 12:00 noon in the Hartford Room, Commons Building, The Institute of Living. (more)
 
(top)
 

 
Current Research Studies (selected list):
  • A 12-Week, Randomized, Phase 2, Double-blind, Parallel-group Study of Two Dose Levels of PF-02545920 Compared to Placebo in the Adjunctive Treatment of Outpatients with Sub-optimally Controlled Symptoms of Schizophrenia - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
  • A 6-Month, Open-label, Multi-center, Flexible-dose Extension Study to the B2061032 Study to Evaluate the Safety, Tolerability and Efficacy of Desvenlafaxine Succinate Sustained-Release (DVS SR) Tablets in the Treatment of Children and Adolescent Outpatients with Major Depressive Disorder (B2061030) - Salma Malik, M.D., M.S., Principal Investigator
  • A 6-Week Randomized, Parallel, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Adolescent subjects with Schizophrenia (D1050301) - Salma Malik, M.D., M.S., Principal Investigator
  • A 6-Week Randomized, Parallel, Double-blind, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects with Irritability Associated with Autistic Disorder (D1050325) - Salma Malik, M.D., M.S., Principal Investigator
  • A 104-Week, Flexible-dose, Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety and Effectiveness of Lurasidone in Pediatric Subjects with Schizophrenia and Subjects with Irritability Associated with Autistic Disorder (D1050302) - Salma Malik, M.D., M.S., Principal Investigator
  • Assessment of a Suicide Screening Program to Improve Detection of Post-Discharge Suicide Risk - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
  • A Double-blind, Doubly-randomized, Placebo-controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE) - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
  • A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Assessed to be at Imminent Risk for Suicide (ESKETINSUI2001) - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
  • Expectancy Therapy and Medication for Smoking Cessation - Adam Jaffe, Ph.D., Principal Investigator; Charles H. Wilber, M.Ed., Co-Investigator
  • A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety and Tolerability of Desvenlafaxine Succinate Sustained-Release (DVS SR) in the treatment of Children and Adolescent Outpatients with Major Depressive Disorder (B2061032) - Salma Malik, M.D., M.S., Principal Investigator
  • An On-going Collaboration with the Mental Health in Independent School Communities Program (Rosemary Baggish, M.Ed., M.P.H. Director and Peter Wells, Ph.D., Senior Consultant) – John W. Goethe, M.D. and Stephen B. Woolley, D.Sc., research consultants
  • Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization (Prospective Randomized Clinical Trial), Gualberto Ruaño M.D., Principal Investigator; John W. Goethe, M.D., et al
  • A Phase III, Multi-center, 4-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents with Bipolar I Disorder (Current or Most Recent Episode Manic) - Salma Malik, M.D., M.S., Principal Investigator
  • A Phase III, Mulit-center, Randomized, 12-week Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients with Sub-optimally Controlled Symptoms of Schizophrenia Treated with Antipsychotics followed by a 40-week, Double-blind, Parellel-group, Placebo-controlled Treatment Period - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator  
  • A Phase III, Mulit-center, Randomized, 24-week Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Stable Patients with Persistent, Predominant Negative Symptoms of Schizophrenia Treated with Antipsychotics followed by a 28-week, Double-blind Treatment Period - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
  • Physiogenomic Analysis of Antipsychotic Therapies and their Metabolic Side Effects - Gualberto Ruaño, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
  • Prevalence of Hyperhomocysteinemia in Patients with Schizophrenia Treated with Atypical Antipsychotics  - Charles Caley, Pharm.D., Principle Investigator
  • Prospective Follow-up Study of the Effects of Locus-of-Control and Life Stressors on Long-Term Outcome of Treatment for Major Depressive Disorder - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
  • Protocol 44-03014-000 NeuroStar® TMS Therapy in Patients with Major Depressive Disorder with Postpartum Onset - John W. Goethe, M.D., Principal Investigator
  • A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) 0.1mg and 0.4mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
  • A Randomized Double-blind, Placebo-controlled, Release Prevention Study with Vilazodone in Patients with Major Depressive Disorder - Andrew Winokur, M.D., Ph.D., Principal Investigator; John W. Goethe, M.D., Co-Principal Investigator
  • Risk of Metabolic Syndrome Among Psychiatric Patients with Major Depressive Disorder Treated with Second-Generation Antipsychotics: Roles of Stress and Inflammation - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
  • SPRITES: Sertraline Pediatric Registry for the Evaluation of Safety - A Non-interventional, Longitudinal, Cohort Study to Evaluate the Effects of Long-term Sertraline Treatment in Children and Adolescents - Scott Hannan, Ph.D., Principal Investigator; Salma Malik, M.D., M.S., Sub-Investigator
  • SSRIs in the Treatment of Major Depressive Disorder: Side Effects and Patient Choices of Treatment - John W. Goethe, M.D., Principal Investigator; Steve Woolley, M.P.H., D.Sc., Co-Principal Investigator
  • Extension of the Longitudinal Study of SSRIs in the Treatment of Major Depressive Disorder: Side Effects and Patient Choices of Treatment - Stephen Woolley, M.P.H., D.Sc., Principal Investigator
  • The Utility of Routine Cytochrome P450 Genotyping in the Selection of Type and Dosage of Antidepressant Medication - John W. Goethe, M.D., Principal Investigator   
(top)
 

 
Selected Publications and Presentations (last updated 5/7/14):
  • Baggish R, Wells PH, Goethe JW, Woolley SB.  Suicide Attempts in Private School Adolescents.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Baggish R, Wells P, Goethe JW, Woolley SB.  Setting the Stage: Suicide Indicators of Risk and Protection Among Private School Students.  Presented at Psychiatric Grand Rounds, The Institute of Living, Hartford, CT, September 10, 2013.
  • Blair EW, Woolley SB, Szarek BL, Mucha TF, Dutka O, Schwartz HI, Goethe JW, Wisniowski J.  Action Research: Testing Interventions to Prevent Violence in Inpatient Psychiatric Settings.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Blair EW, Woolley SB, Szarek BL, Mucha TF, Dutka O, Schwartz HI, Goethe JW, Wisniowski J.  Evidence of the Success of Interventions to Prevent Violence and Reduce Use of Seclusion and Restraint in an Inpatient Psychiatric Setting.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Blair EW, Szarek BL, Woolley SB, Mucha TF, Dutka O, Schwartz HI, Goethe JW.  Variables associated with falls among psychiatric inpatients: The Institute of Living Falls Intervention Initiative.   Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Blair EW, Szarek BL, Azhar N.  Survey of osteoporosis in an inpatient geriatric psychiatric setting: a pilot study.  Issues in Mental Health Nursing, 31(6):403-407, 2010.
  • Blair EW, Szarek BL.  Exploring relationship of psychotropic medication to fall events in an inpatient geriatric psychiatric population.  The International Journal of Psychiatric Nursing Research, 14(1), 2008.
  • Blank K, Szarek BL, Goethe JW.  Metabolic abnormalities in adult and geriatric major depression with and without co-morbid dementia.  The Journal of Clinical Hypertension, 12(6):456-461, 2010.
  • Bonetti J, Szarek BL, Goethe JW.  Current prescribing practices: antipsychotic polypharmacy in patients with schizophrenia and schizoaffective disorder.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Bullock K, Szarek BL, Goethe JW: Racial differences in major depressive disorder presentation. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.
  • Bullock K, Goethe JW, Szarek BL.  Ethnic differences in length of stay and choice of antipsychotic medication among inpatients diagnosed with schizophrenia.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
  • Bullock K, Szarek BL, Goethe JW.  Racial differences in prescribing practices in the treatment of patients diagnosed with schizophrenia.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
  • Caley CF, Thomas M.  Blueprint for change: building a better ADHD treatment regimen for college students.  Presented at the Annual Meeting of the American College Health Association, Chicago, IL, May 2012.
  • Caley CF.  Evaluating Poor Treatment Outcomes: Clinical Pharmacokinetic Considerations.  Presented to medical staff for Grand Rounds, Riverview Hospital, Middletown, CT, January 2012.
  • Caley CF.  Antidepressants: Addressing Key Safety Issues.  Presented to pharmacists at the annual December CE event sponsored by the Connecticut Pharmacists Association, Marriott Hotel, Rocky Hill, CT, December 2011.
  • Caley CF.  Applying Medication Therapy Management to Mental Health.  Presented to attendees at the annual New England Pharmacists Convention, MGM Foxwoods Casino, Ledyard, CT, September 2011.
  • Caley CF.  Influence of CYP2 Genotyping on Psychiatric Pharmacist Consultations.  Presented to attendees at the Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Phoenix, AZ, May 2011.
  • Caley CF. Interpreting and applying CYP450 genomic test results to psychotropic medications. J Pharm Pract, 24(5):439–6, 2011.
  • Caley CF, Goethe JW, Woolley SB, Bardack D, Martello T, Azhar N.  Lifestyle, socioeconomics, and health history versus medications as predictors of metabolic syndrome.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
  • Caley CF.  Psychiatric pharmacy in a university student health system.  Poster presentation at the 11th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Scottsdale, AZ, April 2008.
  • Caley CF, Sopko M.  Chronic leukocystosis associated with clozapine treatment.   Poster presentation at the 11th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Scottsdale, AZ, April 2008.
  • Caley CF.  More than the baby blues:  identification and management of postpartum depression.  Presented at the 155th Annual Meeting and Exposition of the American Pharmacy Association, Georgia Convention Center, Atlanta, Georgia, March 18, 2007.
  • Cardoni AA.  Opiod Dependence: From Cold Turkey to Acute Detox.  Psychopharmacology/Neuroscience Rounds, Institute of Living, Hartford, CT, February 16, 2011.
  • Cardoni AA.  Opiod Dependence: Clinical Pharmacology and Treatment.  Presented at the Henry A. Palmer C.E. Finale 2010, Storrs, CT, December 17, 2010.
  • Cardoni AA.  Management of Treatment-Resistant Depression - An Update.  Presented at the 33rd Annual Arthur E. Schwarting Pharmacy Practice Symposium, Storrs, CT, May 27, 2010.
  • Diefenbach GJ, Assaf M, Bragdon LB, Goethe JW, Hyatt C, Tolin D.  A Randomized, Double-Blind, Sham-Controlled Clinical Trial of rTMS for Generalized Anxiety Disorder.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Diefenbach GJ, Bragdon L, Goethe JW.  Treating anxious depression using repetitive transcranial magnetic stimulation. J Affect Dis, 151:365–8, 2013.
  • Diefenbach GJ, Goethe JW.  Effectiveness of transcranial magnetic stimulation (TMS) for anxious depression.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Diefenbach GJ, Woolley SB, Goethe JW.  The association between self-reported anxiety symptoms and suicidality.  Journal of Nervous and Mental Disease, 197(2):92-97, 2009.
  • Diefenbach GJ, Woolley SB, Goethe JW.  Anxiety symptoms among psychiatric outpatients: prevalence and association with suicide risk.  Poster presented at the Annual Meeting of the American Public Health Association, Washington, DC, November 2007.
  • Ehret M, Szarek BL, Goethe JW.  Is antidepressant use in bipolar disorder associated with readmission?  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Ehret MJ, Szarek BL, Goethe JW.  Current prescribing practices: antidepressant use in schizophrenia. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Ehret MJ, Goethe JW, Szarek BL.  Who received guideline-based pharmacotherapy for bipolar depression?  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
  • Goethe JW, Wisniowski J, Szarek BL, Woolley SB.  Metabolic Syndrome Associated with Severity of Illness and Outcomes among Inpatients with Mood Disorders.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Goethe JW.  Psychoanalytic theory informs “biological” psychiatry.  Presented at the Annual Meeting of the World Psychiatric Association, Vienna, Austria, October 2013.
  • Goethe JW, Szarek BL, Chmielecki L, Ruaño G, Seip R.  The case for routine genotyping in the management of patients with MDD.  Presented at the Annual Meeting of the World Psychiatric Association, Vienna, Austria, October 2013.
  • Goethe JW, Szarek BL, Woolley SB.  Changes in pharmacotherapy in severe major depressive disorder:  a 12-month study of physician and patient treatment decisions.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Goethe JW, Szarek BL, Woolley SB.  Is posttraumatic stress disorder associated with increased risk of metabolic syndrome among inpatients with mood disorders?  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Goethe JW, Szarek BL.  Diagnostic stability in major depressive disorder with versus without psychotic features.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Goethe JW, Szarek BL.  Inpatients with psychotic vs. nonpsychotic MDD: prevalence and clinical characteristics. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.  
  • Goethe JW, Szarek BL, Caley CF.  Metabolic syndrome in psychiatric inpatients treated for depression.  In Thakore J, Leonard Be (eds), Metabolic Effects of Psychotropic Drugs, Modern Trends in Pharmacopsychiatry, Basel Karger, 26:90-104, 2009.
  • Goethe JW.  Stuck in the black box: a patient safety approach to prescribing antidepressants.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
  • Goethe JW, Woolley SB, Cardoni AA, Woznicki B, Piez DA.  Long-term follow-up of patients with major depressive disorder:  changes in symptoms, treatment and side effects.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
  • Goethe JW, Woolley SB, Cardoni AA, Woznicki B, Piez DA.  Selective serotonin reuptake inhibitor discontinuation:  side effects and other factors that influence medication adherence.  J Clin Psychopharmacol, 27(5):451-8, 2007.
  • Goethe JW, Woolley SB, Piez DA, Woznicki B.  Hopelessness and suicidality three months post-hospital discharge.  Presented at the Annual Meeting of the American Psychiatric Association, Toronto, Canada, May 2006.
  • Grgas M, Washburn Jr. CF, Caley CF. Clozapine-Induced Myocarditis: Two Case Reports. Poster to be presented at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, Florida, April 2009.
  • Grgas M, Woolley SB, Ruaño G, Goethe JW, Szarek BL, Caley CF, Ehret MJ. An Analysis of CYP450 Genotype and Patients' Perceived Response and Tolerance to their Antidepressants. Poster to be presented at the 12th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Jacksonville, Florida, April 2009.
  • Levin GM, Bowles TA, Ehret MJ, et al.  Assessment of human serotonin 1A receptor polymorphisms and SSRI responsiveness.  Mol Diag Ther, 11(3):155-60, 2007.
  • Luque CA, Ehret MJ, Rey JA.  Rimonabant (Acomplia): the first cannabinoid-1 receptor blocker for obesity.  P&T, 32(4):209-213, 2007.
  • Padole A, Woolley SB, Szarek BL, Goethe JW.  Variables Associated with 3-Month Incidence of Readmission: Patients with Schizophrenia versus Schizoaffective Disorder. Poster presentation at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Popish SJ, Levin GM, Muthusamy K, Pandya N, Ehret MJ, Rathinavelu A.  Assessment of Ethnicity on the Butyrylcholinesterase Variant K Polymorphism.  Poster presented at the 11th Annual CPNP Meeting (Co-PI) Scottsdale, Arizona, April 2008.
  • Ruaño G, Seip RL, Szarek BL, Schwartz HI, Goethe JW.  Rate of Patient Readmission Following Psychiatric Hospitalization for Major Depressive Disorder Correlated with Innate CYP2D6 Function.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Ruaño G, Szarek BL, Villagra D, Gorowski K, Kocherla M, Seip RL, Goethe JW, Schwartz HI.  Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomarkers in Medicine, 7(3): 429-439, 2013.
  • Ruaño G, Seip RL, Gorowski K, Szarek B, Schwartz HS, Goethe JW.  Changes in psychotropic prescription during hospitalization of depressed patients correlated with innate CYP2D6 function. Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Ruaño G, Gorowski K, Szarek BL, Seip R, Kocherla M, Goethe JW.   High prevalence and significant pharmacokinetic implications of the CYP2C19 ultra-rapid allele *17 allele in psychotropic-treated patients.  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Ruaño G, Villagra D, Szarek B, Windemuth A, Kocherla M, Gorowski K, Berrezueta C, Schwartz HI, Goethe JW.  Physiogenomic analysis of CYP450 drug metabolism correlates dyslipidemia with pharmacogenetic functional status in psychiatric patients.  Biomarkers in Medicine, 5(4):439-449, 2011.
  • Ruaño G, Villagra D, Szarek BL, Windemuth A, Kocheria M, Berrezueta CD, Goethe JW.  Dyslipidemia in psychotropic-treated patients correlates with combinatorial CYP405 drug metabolism indices. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Ruaño G, Villagra D, Szarek BL, Windemuth A, Kocheria M, Goethe JW: Longer hospitalization associated with combinatorial CYP450 drug metabolism deficiencies. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010
  • Ruaño G, Goethe JW, Windemuth A, Szarek BL.  Greater utilization of psychiatric services is associated with CYP450 drug metabolism deficiencies.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
  • Ruaño G, Villagra D, Rahim US, Windemuth A, Kocheria M, Bower B, Szarek BL, Goethe JW.  Increased carrier prevalence of deficient CYP2C9, CYP2C19 and CYP2D6 alleles in depressed patients referred to a tertiary psychiatric hospital.  Personalized Medicine, 5:579-587, 2008.
  • Ruaño G, Goethe JW, Windemuth A, Szarek BL.  Combinatorial cyp450 genotyping for depressed inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
  • Schwartz HI, Goethe JW, Szarek BL, Woolley SB.  Data available on admission predict 30-day readmission in psychiatric inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Schwartz HI, Woolley SB, Goethe JW, Szarek BL.   Inpatient psychiatric care: consequences of short LOS.  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Shelton D, Ehret MJ.  Psychotropic Medication Adherence Patterns Among Adult Inmates.  Platform Presentation at the NCCHC Meeting, Correctional Mental Health: From Innovation to Practice, Las Vegas, Nevada, July 2008.
  • Shelton D, Ehret MJ, Wakai S.  Psychotropic Medication Adherence: Implications for Post-Release Success.  Poster presented at the 11th Annual CPNP Meeting (Co-PI), Scottsdale, Arizona, April 2008.
  • Shelton D, Ehret MJ, Wakai S.  Psychotropic Medication Adherence Among Adult Inmates.  Poster presented at the 20th Annual Scientific Conference Eastern Nursing Research Society, Philadelphia, PA, March 2008.
  • Sopko MA, Ehret MJ, Woolley SB, Szarek BL, Goethe JW.  Rehospitalization rates among patients with schizophrenia.  Presented at the 11th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs, CO, April 2008.
  • Stevens MC, Szarek BL, Goethe JW.  Current prescribing practices: antipsychotic use in children and adolescents.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Stevens MC, Goethe JW, Francois DE, Szarek BL, Piez D.  Metabolic symptoms in adolescent inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
  • Szarek BL, Goethe JW, Woolley SB.  Course of illness over 12 months in patients with major depressive disorder.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Szarek BL, Goethe JW, Chmielecki L.  Diagnostic stability in patients with DSM-IV diagnosis of bipolar disorder.  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Szarek BL, Goethe JW.  Patterns of antipsychotic use in hospitalized psychiatric patients.  Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Szarek BL, Goethe JW.  Metabolic syndrome in psychiatric inpatients: The role of valproate and lithium.  Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.
  • Szarek BL, Goethe JW, Woolley SB.  Assessing metabolic syndrome: waist circumference versus BMI.  Schizophrenia Research, 108(1-3):295-296, 2009.
  • Szarek BL, Goethe JW. Diagnostic stability in patients with schizophrenia, schizoaffective and bipolar disorder.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
  • Szarek BL, Goethe JW, Woolley SB.  Evidence-based medicine and outcome: three month follow-up of inpatients with MDD.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
  • Szarek BL, Goethe JW, Woolley SB.  Indicators of treatment refractory illness and risk of suicide.  Presented at the Annual Meeting of the American Psychiatric Association, San Diego, California, May 2007.
  • Villagra D, Goethe JW, Schwartz HI, Szarek B, Kocherla M, Gorowski K, Windemuth A, Ruaño G.  Novel drug metabolism indices for pharmacogenetic functional status based on combinatorial genotyping of CYP2C9, CYP2C19 and CYP2D6 genes.  Biomarkers in Medicine, 5(4):427-438, 2011.
  • Windemuth A, de Leon J, Goethe JW, Schwartz HI, Woolley SB, Susce M, Kocherla M, Bogaard K, Holford TR, Seip RL, Ruaño G.  Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.  Progress in Neuro-Psychopharmacology and Biological Psychiatry, 36(2):213-219, 2012.
  • Wisniowski J, Woolley SB, Goethe JW, Klein L, Szarek BL, Pizzuto B.  Characteristics of Adult Psychiatric Patients Readmitted Within 30 Days After Psychiatric Hospitalization.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Woolley SB, Terrell K, Goethe JW.  Psychiatric Patients’ Self-Assessment of Body Weight is Associated with Risk of Metabolic Syndrome.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
  • Woolley SB, Goethe JW.  Risk factors for post discharge suicidality among child and adolescent psychiatric inpatients.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2013.
  • Woolley SB, Goethe JW, Cohn RL.  Insomnia, anxiety, and suicidal ideation.  Presented at the Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 2012.
  • Woolley SB, Goethe JW, Szarek BL.  Risks of Readmission in Patients Diagnosed with Bipolar, Major Depressive, or Schizoaffective Disorders: a Longitudinal Study. Presented at the Annual Meeting of the American Psychiatric Association, Honolulu, Hawaii, May 2011.
  • Woolley SB, Cardoni AA, Goethe JW.  An additional source of bias in antidepressant and other trials (authors' reply).  Pharmacotherapy, 30:117e-8e, 2010.
  • Woolley SB, Goethe JW, Szarek BL, Tronsky M. The Association between pre-admission suicidality and readmission was modified by patient experiences, feelings and characteristics. Presented at the Annual Meeting of the American Psychiatric Association, New Orleans, LA, 2010.  
  • Woolley SB, Cardoni AA, Goethe JW.  Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies. Pharmacotherapy, 29:1408-16, 2009. 
  • Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T.  Schizophrenia-Spectrum disorders were associated with cardiovascular disease symptoms, independent of known risk factors for symptoms.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009.
  • Woolley SB, Fredman L, Goethe JW, Lincoln AK, Heeren T.  Headache complaints and the risk of suicidal thoughts or behaviors.  J Nerv Ment Dis, 196(11): 822-828, 2008.
  • Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T.  Patients’ involvement in treatment decisions and antidepressant discontinuation.  Presented at the Annual Meeting of the American Psychiatric Association, Washington, D.C., May 2008.
  • Woolley SB, Goethe JW, Fredman L, Lincoln A, Heeren T.  Severe headaches and the risk of subsequent suicidal thoughts or behaviors.  Presented at the Annual Meeting of the American Psychiatric Association, San Diego, California, May 2007.
  • Woznicki B, Woolley SB, Goethe JW, Bardack S, Azhar N.  Locus of control, life events, treatment history and longitudinal outcomes of treatment for depression.  Presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA, May 2009. 
  • Wootton B, Bragdon LB, Diefenbach GJ, Goethe JW, Tolin D.  Transcranial Magnetic Stimulation for Depression also Improves Anxiety Symptoms: A Meta-Analysis of Randomized-Controlled Trials.  Presented at the Annual Meeting of the American Psychiatric Association, New York, NY, May 2014.
(top